Leprosy primary prevention: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Primary prevention== | ==Primary prevention== | ||
Considering the importance of early [[diagnosis]] and [[Therapy|treatment]] of leprosy, in order to prevent lifetime damage in patients, [[primary prevention]] gains an extraordinary importance, particularly in areas of the world with higher [[incidence]] of the disease. | Considering the importance of early [[diagnosis]] and [[Therapy|treatment]] of leprosy, in order to prevent lifetime damage in patients, [[primary prevention]] gains an extraordinary importance, particularly in areas of the world with higher [[incidence]] of the disease. | ||
Unfortunately up to today, there is still no adequate tool for the early detection of leprosy. Immunoprophylaxis studies in different population groups with the [[BCG vaccine]], alone or in combination with killed [[Mycobacterium leprae]] or [[atypical Mycobacteria]], have shown an [[efficacy]] of 28 to 60%. To the best of today's knowledge, a good coverage of [[BCG vaccine]] is still a major contribution to reduce the impact of leprosy in the populations. | Unfortunately up to today, there is still no adequate tool for the early detection of leprosy. Immunoprophylaxis studies in different population groups with the [[BCG vaccine]], alone or in combination with killed [[Mycobacterium leprae]] or [[atypical Mycobacteria]], have shown an [[efficacy]] of 28 to 60%. To the best of today's knowledge, a good coverage of [[BCG vaccine]] is still a major contribution to reduce the impact of leprosy in the populations.<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref> | ||
[[Chemoprophylaxis]] of [[chronic]] [[infectious diseases]] has also shown benefit, particularly in populations with higher [[Risk factor|risk]] of [[infection]] with leprosy. However, it is still early to define [[chemoprophylaxis]] as a [[public health]] measure, as more [[Clinical trial|trials]] are needed to demonstrate [[safety]], [[efficacy]] and [[cost-effectiveness]] of these [[therapies]]. | [[Chemoprophylaxis]] of [[chronic]] [[infectious diseases]] has also shown benefit, particularly in populations with higher [[Risk factor|risk]] of [[infection]] with leprosy. However, it is still early to define [[chemoprophylaxis]] as a [[public health]] measure, as more [[Clinical trial|trials]] are needed to demonstrate [[safety]], [[efficacy]] and [[cost-effectiveness]] of these [[therapies]].<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref> | ||
Other important element of [[primary prevention]] is the education of populations. Immediate contacts of leprosy patients have higher [[Risk factor|risk]] of being [[infected]], therefore they should be aware of the condition, its [[transmission]] and what to do to minimize [[Risk factor|risk]] of [[infection]].<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref> | Other important element of [[primary prevention]] is the education of populations. Immediate contacts of leprosy patients have higher [[Risk factor|risk]] of being [[infected]], therefore they should be aware of the condition, its [[transmission]] and what to do to minimize [[Risk factor|risk]] of [[infection]].<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref> | ||
Revision as of 01:19, 5 July 2014
|
Leprosy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Leprosy primary prevention On the Web |
|
American Roentgen Ray Society Images of Leprosy primary prevention |
|
Risk calculators and risk factors for Leprosy primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Primary prevention
Considering the importance of early diagnosis and treatment of leprosy, in order to prevent lifetime damage in patients, primary prevention gains an extraordinary importance, particularly in areas of the world with higher incidence of the disease. Unfortunately up to today, there is still no adequate tool for the early detection of leprosy. Immunoprophylaxis studies in different population groups with the BCG vaccine, alone or in combination with killed Mycobacterium leprae or atypical Mycobacteria, have shown an efficacy of 28 to 60%. To the best of today's knowledge, a good coverage of BCG vaccine is still a major contribution to reduce the impact of leprosy in the populations.[1]
Chemoprophylaxis of chronic infectious diseases has also shown benefit, particularly in populations with higher risk of infection with leprosy. However, it is still early to define chemoprophylaxis as a public health measure, as more trials are needed to demonstrate safety, efficacy and cost-effectiveness of these therapies.[1]
Other important element of primary prevention is the education of populations. Immediate contacts of leprosy patients have higher risk of being infected, therefore they should be aware of the condition, its transmission and what to do to minimize risk of infection.[1]